Pepti Review: $99 Semaglutide and a Ladder That Contradicts It

Pepti (hellopepti.com) sells 68 prescription items through a single-page app, and the GLP-1 line is the cheapest we filed in a batch of seven telehealth sellers screened together in August 2026. It is also the only one of the seven we finished with an open question we could not close. Both facts belong in the same paragraph, because a reader deciding whether to start here needs them together rather than in the order a marketing page would put them.

The prices the site renders

Injectable semaglutide is $99 a month and injectable tirzepatide is $199 a month, each with a one-time purchase option at 1.25 times the subscription figure — $124 and $249.¹ The subscription is cancel-anytime with no minimum term, effective at the end of the billing cycle, and it can be paused for up to 90 days, which is a genuinely useful feature if you need to come off treatment for a procedure or a pregnancy plan and expect to come back.

The site's own cost page states the thing that matters most for insulin resistance: one flat monthly price at every titration dose.¹ If that holds, moving from 0.25 mg to 2.4 mg costs nothing extra, and the decision about whether to climb stays a clinical decision rather than a budget one. That is the opposite of how most of this market is priced.

The contradiction we could not resolve

Sitting in Pepti's production data, on the semaglutide and tirzepatide pages, is a per-dose price ladder that no part of the site renders and nothing appears to consume: semaglutide at $299 for 0.25 mg rising to $449 at 2.4 mg, tirzepatide at $349 for 2.5 mg rising to $549 at 15 mg. It contradicts the flat-price headline directly, and it averages roughly three times it.

We file the rendered figures — $99 and $199 — because they are what the page shows, what the catalog object carries, and what the cost page and three separate cross-sell surfaces all repeat. But the checkout endpoint accepts only POST requests, so we could not walk a real order to a real total and settle it. This is reported as unresolved rather than resolved in either direction. If you are considering Pepti, the specific thing to confirm before you enter a card is what you will be charged at 1.0 mg and at 2.4 mg, in writing, and not what the pricing page says at 0.25 mg. That question is worth asking of any program, and it is the one our guide to insulin resistance and GLP-1 medicines keeps returning to, because titration is where a metabolic response is usually found and where a price usually moves.

Thirty-six states, not fifty

Four independent surfaces on Pepti's own site — its shipping page, its state-availability page, its providers page and its homepage title — publish a list of 36 states. Its terms of service say the service is available in 50. The 36-state list is corroborated four ways and the terms line is the outlier, so 36 is the figure we treat as operative. At-home lab testing is a separate matter and ships to all 50.

When the card is charged

Pepti's how-it-works page says you pay nothing until a physician approves your treatment. Its refund policy says payment is collected at checkout, before a licensed provider reviews your intake. Those cannot both be true. The refund policy is the operative document, so assume you are charged first and refunded if you are turned down — the published terms put a provider denial at a full refund within five to ten business days, with no refund once medication has shipped.

The clinicians, and what is missing behind them

Two prescribers are named with full biographies: a medical director in family medicine licensed in 26 named states, and a chief medical officer in internal medicine licensed in 15. That is more disclosure than most of this cohort offers. Neither NPI is published, though, which means neither record can be checked against the national registry the way The Edit's medical director can be. The dispensing pharmacy is never named at all — the site describes it only as an independent FDA-registered 503A or 503B facility. The legal entity is registered at a Newark, Delaware address of the kind used by registered agents rather than by operating businesses.

The rest of the shelf, and the part to leave alone

Beyond the GLP-1 line, Pepti sells a deep peptide and nootropic catalog: BPC-157 at $209 a month, a BPC-157 and TB-500 stack at $289, KPV at $229, NAD+ at $179 injected or $219 nasal, sermorelin and tesamorelin at $189 each, DSIP for sleep at $189, and injectable or nasal PT-141 at $199 and $189. It also sells at-home hormone and metabolic panels at $199, or $169 with an active plan, which is the kind of thing worth pricing against what your own clinician can order — our guide to labs and monitoring on GLP-1 sets out what a real baseline panel includes.

Three items on that shelf we will not describe as options: retatrutide, melanotan II and IGF-1 LR3. Retatrutide holds no FDA approval in any form or jurisdiction. A prescription seller carrying an investigational shelf beside its approved-molecule line is not automatically disqualifying, but it is a fact about the operator, and it belongs in the same view as the $99.

The FDA screen

We queried the FDA's live warning-letter index in August 2026 for the brand and for its legal entity. Nothing matched in the company column.² The neighborhood is worth a sentence: several peptide sellers with similar names do carry letters, and Pepti is not among them. As with every provider in this batch, the same pass returned a known 2026 letter for an unrelated telehealth seller used as a positive control, so the zero is evidence rather than a query that quietly failed.

Where it lands

On the three things this site cares about — can you keep getting it, can you titrate without a price jump, can you stop without a penalty — Pepti answers the first and third cleanly and leaves the second genuinely open. That is an unusual shape for a review to end in, and we would rather publish it than round it off. Compare the mechanism in our semaglutide versus tirzepatide guide, and the rubric we score ranking providers against on our methodology page. Pepti is not in that ranking: it is a non-partner, we earn nothing from it, and this write-up exists so the cheapest number in the batch does not go uninspected.